This research study is studying a drug as a possible treatment for Angiosarcoma or
Epithelioid hemangioendothelioma (EHE).
-The drug involved in this study is Eribulin
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific
disease but it has been approved for other uses.
In this research study, the investigators are studying how safe and effective eribulin is in
participants with Angiosarcoma or EHE.
Eribulin was created to mimic the structure of a chemical that is released from a sea sponge.
The investigators believe that this drug has anti-cancer effects on tumors by blocking
proteins called microtubules, among other functions. It may work by preventing the cancer
cells from dividing and eventually cause the tumor cells to die similar to other drugs that
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.